Content
Geneoscopy
completed $6.9 million Series A Round funding. Investors include
Cultivation Capital (lead), Lightchain Capital.
About
Geneoscopy has developed a novel methodology to reliably and consistently extract stool-derived eukaryotic RNA (seRNA) transcripts and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of seRNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the detection and prevention of colorectal cancer in human and a diagnostic test to differentiate GI lymphoma from inflammatory bowel disease (IBD) in cats. Geneoscopy is also exploring the use of its technology for other gastrointestinal applications in both humans and animals.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.


Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
